BRÈVE

sur IMPLANET (EPA:ALIMP)

IMPLANET: 50% growth in turnover in the third quarter of 2024

Graphique de l'évolution du cours de l'action IMPLANET (EPA:ALIMP).

IMPLANET, a medical technology company, recorded revenue of €2.3 million in the third quarter of 2024, up 50% compared to 2023. In the first nine months of the year, revenue amounted to €6.4 million, up 11% compared to the previous year. In the United States, the first delivery of Olea equipment generated €0.5 million, thanks to the partnership with elliquence.

In France, quarterly sales increased by 7% to €0.78 million. In the United States, they increased by 32% to €0.30 million. However, sales in the rest of the world decreased by 22%. The medical equipment division benefited from significant growth, with sales of €0.79 million, compared to €0.03 million last year, supported by the introduction of the Olea ultrasonic scalpel.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de IMPLANET